Biocon Ltd.
Industry Group: Pharmaceuticals
Country/Region: India
Identifier: BOM:532523
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 131 out of 909
Universe
Global Universe 6109 out of 16009
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Ultragenyx Pharmaceutical, Inc. |
18
Low
|
58 out of 909 |
Biocon Ltd. |
22
Medium
|
131 out of 909 |
Madrigal Pharmaceuticals, Inc. |
26.2
Medium
|
283 out of 909 |
Changchun High-Tech Industry (Group) Co., Ltd. |
27.9
Medium
|
412 out of 909 |
Akeso, Inc. |
32.3
High
|
621 out of 909 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Biocon Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Biocon Ltd.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Biocon Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level
![blurred controversy level](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-level-blur.jpg)
Contributing Events
![blurred controversy events](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-blur.jpg)
Highest Controversy Events Locations
![world map blurred](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-map-blur.jpg)